Compass Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Compass Therapeutics
CMPX Stock  USD 5.14  0.15  3.01%   
Compass Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Compass Therapeutics' valuation are provided below:
Market Capitalization
914.2 M
Enterprise Value Revenue
109.2827
Earnings Share
(0.45)
We have found one hundred twenty available fundamental signals for Compass Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Compass Therapeutics prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 410.5 M in 2025, whereas Enterprise Value is likely to drop slightly above 176.9 M in 2025.
Check Compass Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Compass Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 7.7 M or Interest Income of 7.7 M, as well as many indicators such as Price To Sales Ratio of 187, Dividend Yield of 0.0 or PTB Ratio of 1.71. Compass financial statements analysis is a perfect complement when working with Compass Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Compass Stock
Check out the analysis of Compass Therapeutics Correlation against competitors.
For more information on how to buy Compass Stock please use our How to Invest in Compass Therapeutics guide.

Compass Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets125.3 M140.4 M90 M
Slightly volatile
Short and Long Term Debt Total6.2 M6.6 M11.2 M
Slightly volatile
Other Current Liabilities5.4 M6.3 M2.6 M
Slightly volatile
Total Current Liabilities11.3 M8.9 M9.4 M
Slightly volatile
Property Plant And Equipment Net4.9 M7.1 M4.9 M
Pretty Stable
Current Deferred Revenue2 M3.6 M1.6 M
Slightly volatile
Accounts Payable2.2 M2.2 M1.9 M
Slightly volatile
Cash43.1 M43.5 M55 M
Pretty Stable
Non Current Assets Total5.3 M7.7 M5.3 M
Pretty Stable
Non Currrent Assets Other411.4 K568 K246.8 K
Slightly volatile
Long Term Debt1.6 M1.7 M7.5 M
Slightly volatile
Cash And Short Term Investments116.3 M126.7 M82.3 M
Slightly volatile
Common Stock Total Equity11.1 K11.7 K1.6 M
Slightly volatile
Common Stock Shares Outstanding85.7 M137.1 M42 M
Slightly volatile
Liabilities And Stockholders Equity125.3 M140.4 M90 M
Slightly volatile
Non Current Liabilities Total6 M6.3 M89.2 M
Slightly volatile
Other Current Assets3.7 M6 M2.4 M
Slightly volatile
Total Liabilities14.4 M15.2 M98.4 M
Slightly volatile
Property Plant And Equipment Gross8.5 M13.4 M6.6 M
Slightly volatile
Short and Long Term Debt6.1 M8.6 M5.2 M
Slightly volatile
Total Current Assets120 M132.8 M84.7 M
Slightly volatile
Capital Stock11.1 K11.7 K1.6 M
Slightly volatile
Net Working Capital108.7 M123.9 M75.3 M
Slightly volatile
Short Term Debt321.1 K338 K3.1 M
Slightly volatile
Common Stock11.1 K11.7 K1.3 M
Slightly volatile
Property Plant Equipment1.3 M1.4 M4.1 M
Slightly volatile
Long Term Debt Total1.5 M1.7 M1.8 M
Slightly volatile
Capital Surpluse373.9 M523 M267.8 M
Slightly volatile
Non Current Liabilities Other8559002.3 M
Slightly volatile
Net Receivables256 K288 K314 K
Slightly volatile

Compass Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income7.7 M7.3 M2 M
Slightly volatile
Depreciation And Amortization1.6 M1.8 M1.9 M
Pretty Stable
Interest Expense2.8 M2.7 M1.2 M
Slightly volatile
Selling General Administrative13.5 M15.1 M11.8 M
Slightly volatile
Other Operating Expenses52.1 M57.5 M43.1 M
Slightly volatile
Research Development30.7 M42.3 M27.7 M
Slightly volatile
Cost Of Revenue1.6 M1.7 M1.9 M
Slightly volatile
Total Operating Expenses52.1 M57.5 M43.1 M
Slightly volatile
Reconciled Depreciation1.6 M1.8 M1.9 M
Pretty Stable
Selling And Marketing Expenses8.8 M9.9 M10.8 M
Slightly volatile

Compass Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation4.7 M8.6 M2.5 M
Slightly volatile
Begin Period Cash Flow23 M24.2 M38.9 M
Pretty Stable
Depreciation1.6 M1.8 M1.9 M
Pretty Stable
Capital Expenditures41.8 K44 K1.3 M
Slightly volatile
Issuance Of Capital Stock17.2 M18.1 M50.4 M
Pretty Stable
Total Cash From Financing Activities16.5 M17.3 M53.5 M
Slightly volatile
End Period Cash Flow43.2 M43.5 M55.2 M
Pretty Stable
Change To Netincome5.7 M6 M5.5 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio187210230
Slightly volatile
Stock Based Compensation To Revenue8.069.069.8818
Slightly volatile
Capex To Depreciation0.02380.02510.6793
Slightly volatile
EV To Sales152171187
Slightly volatile
Payables Turnover0.50.531.2224
Very volatile
Sales General And Administrative To Revenue14.2416.0217.4693
Slightly volatile
Research And Ddevelopement To Revenue39.8544.8348.8799
Slightly volatile
Capex To Revenue0.04140.04660.0508
Slightly volatile
Cash Per Share0.880.92426.995
Slightly volatile
Days Payables Outstanding746711395
Slightly volatile
Income Quality0.650.90850.8352
Pretty Stable
Net Debt To EBITDA0.640.67151.2483
Very volatile
Current Ratio8.5914.95958.7128
Slightly volatile
Capex Per Share3.0E-43.0E-40.2297
Slightly volatile
Revenue Per Share0.0050.00560.0061
Slightly volatile
Interest Debt Per Share0.0460.04841.7909
Slightly volatile
Debt To Assets0.04490.04720.1792
Slightly volatile
Days Of Payables Outstanding746711395
Slightly volatile
Ebt Per Ebit1.060.8720.9855
Slightly volatile
Quick Ratio8.5914.95958.7128
Slightly volatile
Net Income Per E B T1.091.081.0049
Pretty Stable
Cash Ratio5.944.96.1303
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.121.0011.0479
Pretty Stable
Fixed Asset Turnover0.0960.110.1179
Slightly volatile
Debt Ratio0.04490.04720.1792
Slightly volatile
Price Sales Ratio187210230
Slightly volatile
Asset Turnover0.00480.00540.0059
Slightly volatile

Compass Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap410.5 M228.6 M383.9 M
Slightly volatile
Enterprise Value176.9 M186.3 M350.9 M
Slightly volatile

Compass Fundamental Market Drivers

Compass Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Compass Therapeutics Financial Statements

Compass Therapeutics investors use historical fundamental indicators, such as Compass Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Compass Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue3.6 M2 M
Total Revenue850 K892.5 K
Cost Of Revenue1.7 M1.6 M
Stock Based Compensation To Revenue 9.06  8.06 
Sales General And Administrative To Revenue 16.02  14.24 
Research And Ddevelopement To Revenue 44.83  39.85 
Capex To Revenue 0.05  0.04 
Ebit Per Revenue(59.96)(62.95)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
DDDupont De Nemours
CRDOCredo Technology Group
GOOGAlphabet Inc Class C

Additional Tools for Compass Stock Analysis

When running Compass Therapeutics' price analysis, check to measure Compass Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Therapeutics is operating at the current time. Most of Compass Therapeutics' value examination focuses on studying past and present price action to predict the probability of Compass Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Therapeutics' price. Additionally, you may evaluate how the addition of Compass Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY